June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Mycophenolate mofetil is neuroprotective in a mouse model of retinitis pigmentosa (RP)
Author Affiliations & Notes
  • Paul Yang
    Ophthalmology, Casey Eye Institute, OHSU, Portland, OR
  • Rachel Lockard
    Ophthalmology, Casey Eye Institute, OHSU, Portland, OR
  • Yuquan Wen
    Baylor Visual Function Center, Baylor University Medical Center, Dallas, TX
  • Richard G Weleber
    Ophthalmology, Casey Eye Institute, OHSU, Portland, OR
  • Mark E Pennesi
    Ophthalmology, Casey Eye Institute, OHSU, Portland, OR
  • Footnotes
    Commercial Relationships Paul Yang, None; Rachel Lockard, None; Yuquan Wen, None; Richard Weleber, None; Mark Pennesi, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 3620. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Paul Yang, Rachel Lockard, Yuquan Wen, Richard G Weleber, Mark E Pennesi; Mycophenolate mofetil is neuroprotective in a mouse model of retinitis pigmentosa (RP). Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):3620.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

Previous evidence in rodent models of RP implicated the role of cGMP cytotoxicity and immune-mediated damage from microglia activation and expression of inflammatory cytokines. Mycophenolate mofetil (MMF), a commonly-used immunomodulatory medication in ocular immunology, is known to deplete precursors of cGMP and inhibit microglia activation. We hypothesize that MMF is neuroprotective in the rd10 mice.

 
Methods
 

The rd10 mice received daily i.p. injections of MMF or vehicle (5% dextrose, D5) prior to any structural evidence of retinal degeneration. Optical coherence tomography (sdOCT) was used to quantify retinal thickness as previously described (Pennesi et al., IOVS, 2012). Postnatal day (p) 22 mice were euthanized and eyes were harvested for IHC. Fixed, OCT-embedded eyes were cryosectioned, mounted, and stored at -200 C. Anti-arrestin and DAPI were used to stain photoreceptors and nuclei, respectively. Anti-CD11b and -F4/80 were used as microglia markers, and anti-TNFɑ was used to assess for inflammation. Two-tailed Student’s t-test was used for statistical analysis.

 
Results
 

The rd10 mice that were treated with MMF 100 mg/kg/d (n=7, 117.3 ± 1.1 µm) from p13-p22 not only had significantly greater outer retinal thickness compared with the D5 group (n=6, 68.9 ± 8.1 µm; p=0.002), but had similar thickness as age-matched c57 mice (n=4, 122.3 ± 1.4 µm); IHC showed normal outer retinal structure with no signs of microglia activation in the MMF group compared with the microglia-laden atrophic retina in the D5 group (figure 1,2). When treatment was initiated just one day later from p14-p22, the neuroprotective effect of MMF on outer retinal thickness was less prominent (n=11, 73.7 ± 6.4 µm), although still significant compared with the D5 group (n=13, 46.8 ± 1.6 µm; p=0.001).

 
Conclusions
 

Treatment with MMF showed significant neuroprotection in rd10 mice, producing robust structural preservation of the retina without signs of microglia activation. The neuroprotective effect was enhanced by earlier treatment, suggesting a critical window of opportunity for therapy. Further examination will be needed to elucidate the neuroprotective mechanisms of MMF.  

 
Figure 1. Effect of MMF on retinal thickness as measured by sdOCT at p22. *, p<0.05.
 
Figure 1. Effect of MMF on retinal thickness as measured by sdOCT at p22. *, p<0.05.
 
 
Figure 2. Top: sdOCT images of retina at p22 from c57 and rd10 mice treated p13-22. Bottom: IHC with DAPI and arrestin (A,B,F), CD11b (C,G), TNFɑ (D,H), and F4/80 (E,I).
 
Figure 2. Top: sdOCT images of retina at p22 from c57 and rd10 mice treated p13-22. Bottom: IHC with DAPI and arrestin (A,B,F), CD11b (C,G), TNFɑ (D,H), and F4/80 (E,I).

 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×